Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 1

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 1
---
 an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth companyx

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨

<div align='center'>INTRODUCTORY NOTE</div>

This Amendment No. 1 on Form
8-K/A (“Amendment No. 1”) amends Item 2.01 and Item 9.01 of the Current Report on Form 8-K filed by Liminatus Pharma, Inc.
(formerly known as Iris Parent Holding Corp.), a Delaware corporation (the “Company” or “ParentCo”), on May 6,
2025 (the “Original Report”), in which the Company reported, among other events, the completion of the Business Combination
(as defined in the Original Report) on April 30, 2025.

This Amendment No. 1 (i) amends
certain disclosures under Item 2.01 of the Original Report to provide an update of developments at the Company or its subsidiaries, subsequent
to the filing date of the Original Report; (ii) amends the financial statements provided under Item 9.01(a) in the Original Report to
include (x) the unaudited financial statements of Liminatus Pharma, LLC, a Delaware limited liability company (“Liminatus”),
as of and for the three months ended March 31, 2025 and the Management’s Discussion and Analysis of Financial Condition and Results
of Operations of Liminatus for the three months ended March 31, 2025 and (y) the unaudited financial statements of Iris Acquisition Corp
(formerly known as Tribe Capital Growth Corp I), a Delaware corporation (“Iris”), as of and for the three months ended March
31, 2025 and the Management’s Discussion and Analysis of Financial Condition and Results of Operations of Iris for the three months
ended March 31, 2025; and (iii) adds the exhibits included below under Item 9.01(d).

Except as set forth herein,
this Amendment No. 1 does not amend any other item of the Original Report or purport to provide an